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Abstract
Background: C. pseudotuberculosis is an important animal pathogen that causes substantial economical loss in
sheep and goat farming. Zoonotic infections in humans are rare, but when they occur they are often severe and
difficult to treat. One of the most studied proteins from this bacterium, the secreted protein CP40 is being
developed as a promising vaccine candidate and has been characterized as a serine protease. In this study we have
investigated if CP40 is an endoglycosidase rather than a protease.
Results: CP40 does not show any protease activity and contains an EndoS-like family 18 of glycoside hydrolase
(chitinase) motif. It hydrolyzes biantennary glycans on both human and ovine IgGs. CP40 is not a general chitinase
and cannot hydrolyze bisecting GlcNAc.
Conclusion: Taken together we present solid evidence for re-annotating CP40 as an EndoS-like endoglycosidase.
Redefining the activity of this enzyme will facilitate subsequent studies that could give further insight into immune
evasion mechanisms underlying corynebacterial infections in animals and humans.
Keywords: CP40, EndoS, IgG, Corynebacterium pseudotuberculosis, Glycosidase, Chitinase, endo-β-N-
acetylglucosaminidase
Background
Glycoproteins are essential for most biological pathways
in eukaryotes and play important roles in the immune
system of mammals [1, 2]. Glycan chains are important
for maintenance of the structure of glycoproteins and
their biological function. Alterations in glycosylation
pattern on glycoproteins involved in the immune system
are associated with disorders such as autoimmunity and
cancer [3, 4]. Immunoglobulin G (IgG) is the most
abundant immunoglobulin in serum and plays a funda-
mental role in the adaptive immune response. The hinge
and CH2 regions in IgG are involved in binding to both
IgG-Fc receptors (FcγR) and the complement factor C1q
(3). There is a conserved N-linked glycosylation site on
asparagine 297 in the CH2 domain of Fc of human IgG
[5]. This N-297 glycosylation is essential for fine tuning
IgG effector functions such as binding to FcγRs and
complement activation [6–8].
Glycosidases are enzymes that catalyze hydrolysis of
glycosidic linkages in glycan chains. There are two kinds of
glycosidases: exoglycosidases that cleave terminal carbohy-
drates from glycan structures, and endoglycosidases that
hydrolyze linkages within the glycan chains. Numerous
glycosidases from bacterial pathogens with activity on
mammalian glycoproteins have been identified and charac-
terized [9]. Some of these glycosidases are used for glycan
engineering and glycan analysis of glycoproteins, or as tools
for glycobiology research and drug development [10].
Endoglycosidases F1, F2 and F3 are important glycosidases
from Elizabethkingia meningoseptica (formerly Flavobacter-
ium meningosepticum) have been used as standard tools for
glycoprotein characterization and glycoengineering. These
endo-β-N-acetylglucosaminidases hydrolyze β-1,4-N-acetyl-
D-glucosamine linkages in the chitobiose core of N-glycans
in glycoproteins [11]. Although PNGase F is an amidase
and not a glycosidase, it is often used in this context as an
important tool able to release most eukaryotic N-glycans by
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catalyzing the hydrolysis of the amide bond between the
reducing end N-acetylglucosamine (GlcNAc) and the
asparagine residue of the glycoprotein [10, 11].
EndoS is a 108 kDa endo-β-N-acetylglucosaminidase
belonging to family 18 of glycoside hydrolases (GH18)
(CAZy, 2016; http://www.cazy.org). It is secreted by the
strictly human pathogen Streptococcus pyogenes [12] and
cleaves the β-1,4 linkage between the two GlcNAcs in
the chitobiose core of the N-linked glycan of IgG [13].
IgG is the preferred substrate for EndoS, and this
enzyme hydrolyzes the N-linked glycan only on native,
but not denatured IgG [14]. This hydrolysis of IgG
glycans most likely contributes to immune evasion by S.
pyogenes during colonization and infection [15, 16]. In
addition, based on the specificity of EndoS, purified
enzyme has been used with success to remove complex
N-linked oligosaccharide structures from the Fc region
both in vitro and in vivo [16–23].
Corynebacterium pseudotuberculosis causes ovine case-
ous lymphadenitis (CLA), an infectious and contagious
disease in sheep and goats. CLA is characterized by
formation of abscesses in superficial lymph nodes and
lesions in subcutaneous tissues. The necrotic lesions can
also develop internally in spleen, kidneys, lungs, and liver.
These infections can reduce meat, wool, and milk produc-
tion, and are a major cause of economic loss in small
ruminant farming [24]. C. pseudotuberculosis is mainly
considered an animal pathogen, but can occasionally
cause lymphadenitis in humans [25]. In 1994, Walker and
colleagues identified a 40 kDa protein secreted by this
bacterium and subsequently showed that vaccination of
sheep with this protein provides a high level of protection
against ovine caseous lymphadenitis CLA [26]. It has been
shown that this 40 kDa protein, denoted CP40, is one of
the predominant antigens recognized at day 7 of infection
by C. pseudotuberculosis in sheep [26]. Subsequent
biochemical analysis of recombinantly expressed CP40
including gelatin zymography and inhibition of enzymatic
activity using protease inhibitors, have suggested that it
has serine protease activity [27], but no further studies of
the enzymatic activity have been conducted.
Since there are sequence similarities between CP40 and
endoglycosidases such as EndoS, we hypothesized that the
annotation of CP40 as a protease is incorrect, and that this
major antigen of C. pseudotuberculosis is rather an endogly-
cosidase with putative activity on host glycoproteins. This
hypothesis is also supported by recent a comparative
genomics study on C. ulcerans [28], but no experimental
evidence has been presented to date.
Methods
Bacterial isolates and growth conditions
The C. pseudotuberculosis type strain DSM-20689 (also
ATCC 19410 and NCTC 3450) was originally recovered
from infected lymphoid tissue from a sheep (DSMZ,
Braunschweig, Germany). Bacteria were cultured in
brain heart infusion (BHI) medium (Oxoid, Hampshire,
England) supplemented with 0.5 % glucose with aeration
at 37 °C for 24 h. Escherichia coli chemically competent
strains Top10 (Invitrogen, Hämeenlinna, Finland) and
BL21 (DE3) pLysE (Life Technologies, Carlsbad, CA)
were propagated on luria broth (LB) agar. For selec-
tion of E. coli Top10, 100 μg ml−1 carbenicillin was
added to medium and for E. coli BL21 in addition of
100 μg ml−1 carbenicillin, 34 μg ml−1 chloramphenicol
was added. E. coli strains were propagated in LB overnight
at 37 °C with aeration. Transformation was carried out
according to manufacturer’s instructions.
Recombinant expression of CP40 and sequencing of the
cp40 gene
Genomic DNA of C. pseudotuberculosis DSM-20689 was
extracted using innuPREP Bacteria DNA Kit (Analytikjena
Biometra, Göttingen, Germany). The coding sequence of
cp40 was amplified by PCR using the oligonucleotide
primers 5′-TGT-AGC-CAT-GGG-CGA-GTC-TGC-AAC-
CTT-3′ and 5′-GAA-AGG-AAA-ACT-GGA-TCC-TCT-
AGA-ACC-AGT-TGG-3′ (The restriction sites for NcoI
and BamHI are italic). The 1140 bp PCR product was
digested with the restriction enzymes NcoI and BamHI
(Thermo Fisher Scientific, New York, NY), and ligated into
pMAL-c5X-His vector (New England Biolabs, Berkeley,
California) using DNA ligase T4 (Thermo Fisher Scientific).
The pMAL-c5X-His vector encodes both Maltose-binding
protein (MBP) and a 6xhistidine (His) tags Generated
pMAL-c5X-His-cp40 plasmid was transformed to E. coli
Top10 chemically competent cells. Plasmids with correct
insert were transformed into the E. coli expression strain
BL21 (DE3) pLysE. Expression of MBP-cp40-His was
induced by 0.1 mM isopropyl-β-D-1-thiogalactopyranoside
(IPTG) (VWR International, Radnor, PA) for 2 h at 37 °C.
The protein CP40 was purified from the pellet of harvested
bacteria according to manufacturer’s protocol using
ProteoSpin™ Inclusion Body Protein Isolation Maxi Kit
(Norgen Biotek CORP. Thorold, Canada). Purified CP40
protein was dialyzed against PBS at 4 °C.
The cp40 gene in DSM-20689 was sequenced by
Sanger sequencing of overlapping PCR products using
the Lightrun sequencing service at GATC Biotech
(Konstanz, Germany).
N-glycan hydrolysis assay
To analyze the activity of CP40 on N-glycans 0.5 μg of
recombinant CP40 was incubated with 1 μg of human
IgG and incubated at 37 °C for 2 h. As a control 0.5 μg
of MBP and PNGase F also were incubated with IgG in
the same condition. The reaction was analyzed by
4–12 % stain-free SDS-PAGE (Bio-Rad Laboratories,
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Hercules, CA). Proteins were transferred to a PVDF
membrane (Bio-Rad Laboratories). Lectin blot was
carried out using a Trans-Blot Turbo Transfer system
(Bio-Rad Laboratories). The membranes were blocked in
lectin buffer (10 mM Hepes, 0.15 M NaCl, 0.1 % Tween
20, 0.01 mM MnCl2 and 0.1 mM CaCl2, pH 7.5) for
20 min and incubated with 2 μg ml−1 of fluorescein
labeled LCA (Lens culinaris agglutinin) (Vector Labora-
tories, Burlingame, CA) in lectin buffer for 45 min. The
membranes were washed three times with lectin buffer
and visualized using a Chemidoc XRS (Bio-Rad Labora-
tories). In addition 1 μg ovine, equine, bovine and
caprine IgG were incubated with 0.5 μg of recombinant
CP40 or EndoS independently at 37 °C for 2 h. In paral-
lel 1 μg of all subclasses of human IgG (Sigma-Aldrich,
St. Louis, MO) (Calbiotech, CA, for IgG2) independently
were incubated with 0.5 μg CP40 in PBS at 37 °C
overnight. The reactions were analyzed by 4–12 % stain-
free SDS-PAGE and LCA blot as described above.
Analysis of glycosidase activity of native CP40 in bacterial
culture
C. pseudotuberculosis DSM-20689 was grown on blood
agar plates at 37 °C. Several colonies were inoculated in
100 ml BHI medium and incubated at 37 °C. After 4 h,
500 μl human plasma was added to the culture medium.
Supernatant (1 ml) was collected from the bacterial
culture after 8, 10, 12 and 24 h. IgG was purified from
the samples using Ab spin trap (GE Healthcare, Little
Chalfont, UK) and analyzed by 4–12 % stain-free
SDS-PAGE and LCA blot as described above. As a
control, 1 μg untreated human IgG was run on the gel.
The optical density of the bacterial culture was mea-
sured at 600 nm at each time point.
Chitinase assay and substrate specificity of CP40
The fluorogenic substrate 4-methylumbelliferyl-N-acetyl-β-
D-glucosaminide (4MU-GlcNAc; 0.2 mM) (Sigma–Aldrich)
was incubated with 2 μg of recombinant CP40 in a total
volume of 100 μl PBS. As controls, 0.3 mU of a chitinase
from Streptomyces griseus (Sigma-Aldrich), 2 μg EndoSd or
2 μg MBP were included. All reactions were incubated for
1.5 h in a black 96-well plate (Thermo Fisher Scientific) at
37 °C. Addition of 100 μl of 0.1 M glycine (pH 10) stopped
the reactions. The assays were carried out using 4 repli-
cates for each reaction. Absorbance at 355/460 nm was
measured using spectrophotometer and data are shown as
mean ± SD. Different response in absorbance were ana-
lyzed statistically using an One-Way ANOVA followed up
by Tukey’s multiple comparisons test, where differences
were considered significant if p < 0.05.
In order to check the substrate specificity of the
enzyme, 0.5 μg of recombinantly expressed CP40 was
incubated with 1 μg of different glycoproteins such as
IgA (Calbiotech), IgE, IgD, IgM, Fetuin, α-1-acid glyco-
protein (AGP), and human lactoferrin (hLF) (all Sigma–
Aldrich) for 2 h at 37 °C. All samples were incubated
with PNGase F under the same conditions as a control.
All reactions were analyzed by stain-free SDS-PAGE
(Bio-Rad Laboratories). In parallel, 1 μg of bovine,
caprine, and equine IgG (Sigma-Aldrich) were incubated
with 0.5 μg CP40 or EndoS overnight at 37 °C. In addition
1 μg of all subclasses of human IgG (Sigma-Aldrich,
Calbiotech for IgG2) were independently incubated with
0.5 μg CP40 in PBS at 37 °C overnight. The results were
analyzed by SDS-PAGE and LCA blot.
Sequence analysis and similarity tree
The sequence of CP40 from C. pseudotuberculosis DSM-
20689 was compared with EndoS and different bacterial
endoglycosidases and serine proteases. Similarity tree
and CP40 active site comparison were generated using
the ClustalW alignment in the MacVector software
suite (version 15.0.3 (34)) (MacVector, Apex, NC). A re-
construction of a phylogenetic tree was performed using
the neighbor-joining systematic method with uncorrected
p-values. To validate the tree, bootstrapping with 10,000
replications was used.
Gelatin zymography
To prepare zymogram, 0.1 % gelatin was embedded in
10 % SDS-polyacrylamide gel. Recombinant CP40 (1 μg)
or supernatant of Pseudomonas aeruginosa as a control
were loaded on gel and run under non-reducing condi-
tions. The zymogram was washed with 2.5 % Triton
X-100 (Sigma-Aldrich) for 1 h and incubated in an en-
zyme assay buffer (50 mM Tris– HCl (pH 7.5), 5 mM
CaCl2, 200 mM NaCl, 1 μM ZnCl2) overnight at 37 °C.
The gel was stained in Coomassie brilliant blue and then
destained with 30 % methanol and 10 % acetic acid.
Analysis of released IgG glycans by HPLC
N-glycans were released from 50 μg of human and
ovine IgG by incubation with 2 μg PNGase F, 2 μg
EndoS or 5 μg CP40 overnight at 37 °C. Glycans were
fluorescently labeled with 2-AB (2-aminobenzamide)
(Sigma-Aldrich) and excess labeling reagents removed by
normal phase PhyTips (PhyNexus, San Jose, CA). HILIC
separation of 2-AB labeled glycans was performed on an
Infinity 1260 HPLC System equipped with an Advanced
Bio Glycan Map column (2.1 mm × 150 mm 2.7 μm) and
a fluorescent detector (all Agilent Technologies, CA). The
column temperature was kept at 60 °C and the flow rate
set to 0.5 ml min−1 using 100 mM ammonium formate
(pH 4.5) against acetonitrile with ammonium formate
increasing from 15 to 25 % from 0 to 5 min, then 25–36 %
from 5 to 35 min. Fluorescence detection was achieved
using excitation and emission wavelengths of 330 nm and
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420 nm respectively. The released IgG N-glycan chro-
matograms has been well established and assigned [29]. In
order to analyze sequence, composition and linkage
specificities of the glycans, exoglycosidase digestion ar-
rays were performed (Prozyme, Hayward, CA). Non-re-
ducing end glycan residues were specifically removed using
1 U ml−1 ABS (Arthrobacter ureafaciens sialidase) to re-
move terminal sialic acid. Terminal galactose and GlcNAc
were removed using 0.5 U ml−1 BTG (bovine testes β-
galactosidase) and 4 U ml−1 GUH (Streptococcus pneumo-
niae hexosaminidase) respectively. To remove core fucose,
1 U ml−1 BKF (Bovine kidney fucosidase) was used.
Results
CP40 is similar to EndoS-like enzymes
CP40 has been described as a serine protease, but when
we searched the protein databases, the protein did not
show any significant sequence similarity with any known
proteases except for nearly identical corynebacterial pro-
teins that most likely are annotated based on the original
characterization of CP40 (data not shown). Instead,
CP40 shows similarity to bacterial endoglycosidases and
contains a putative glycoside hydrolase family 18 (GH18)
domain. We sequenced the cp40 gene in the DSM-
20689 used in this study, and this revealed that the
coding sequence only differs in one nucleotide leading
to one amino acid substation (proline instead of histi-
dine at position 105) compared to cp40 in WA1030 used
in the original characterization of the enzyme [27].
We aligned the sequence of CP40 with a number of
bacterial endoglycosidases as well as serine protease
sequences. The reconstructed phylogentic tree clearly
shows that CP40 clusters with the endoglycosidases rather
than the proteases (Fig. 1, panel a). Furthermore, CP40
forms a distinct subgroup with the most similar enzyme,
EndoE from Enterococcus faecalis (Fig. 1, panel a) [30].
GH18 enzymes contain a conserved consensus se-
quence motif (LIVMFY)-(DN)-G-(LIVMF)-(DN)-(LIV
MF)-(DN)-X-E, where the terminal glutamic acid is
essential for enzymatic activity [31, 32]. When aligning a
putative GH18 active site in CP40 with the most similar
enzymes EndoE and EndoS, it becomes clear that CP40
has a perfect GH18 motif that differs only in one or two
amino acids as compared to the active site of EndoS and
EndoE, respectively (Fig. 1, panel b). The active sites of
both EndoS and EndoE have been confirmed by site-
directed mutagenesis, and interestingly both enzymes
have activity on the N-linked glycans in IgG Fc [13, 30].
Taken together this analysis clearly indicates that CP40
could be a GH18 enzyme and we addressed this hypoth-
esis experimentally by testing for general chitinase activ-
ity, or more specific glycan hydrolyzing activity on host
glycoproteins.
CP40 and C. pseudotuberculosis have glycosidase activity
on IgG
Based on the clear relationship between CP40 and the
known IgG glycan hydrolases EndoS and EndoE, we
speculated that IgG could be a substrate also for CP40.
As CP40 is secreted [26], we cultured C. pseudotubercu-
losis DSM-20689 in medium supplemented with 0.5 %
human plasma. After 8,10,12 and 24 h of culture, IgG
was purified from the culture supernatant and analyzed
by SDS-PAGE and LCA blot (Fig. 2, panels a and b).
After 24 h when the bacteria were in late exponential
phase, a clear mass shift of IgG and a lack of LCA signal
could be observed. However, the LCA signals seemed to
gradually diminish from the 10 h sample to be com-
pletely gone in the 24 h sample. This indicates that C.
pseudotuberculosis does secrete a glycoside hydrolase.
To test if this activity is indeed mediated by CP40, we
recombinantly expressed the enzyme as a maltose-
binding protein (MBP)-fusion protein in E. coli and
incubated the enzyme with pooled polyclonal human
IgG. Glycan hydrolyzing activity was subsequently ana-
lyzed by SDS-PAGE and LCA blot. MBP alone, and
PNGase F were used as controls. A mobility shift of the
IgG heavy chain on SDS-PAGE and a corresponding lack
of signal on the LCA blot (LCA recognizes α-linked
mannose) were observed when IgG was incubated with
CP40 and PNGase F, but not for MBP and the buffer
control (Fig. 3, panel a).
Since C. pseudotuberculosis is primarily an animal
pathogen, we investigated whether animal IgGs are
substrates for CP40. While EndoS was able to hydrolyze
the glycan chain on all tested animal IgGs, as judged by
a ~3 kDa shift of the heavy chain in combination with a
loss of LCA signal, CP40 was only able to fully hydrolyze
equine IgG and partially hydrolyze ovine IgG, but
showed no activity on bovine or caprine IgG (Fig. 3,
panel b). To further evaluate the glycan hydrolyzing
activity of CP40, we incubated CP40 with the four
subclasses of human IgG. This revealed that CP40 has
activity versus all human IgG subclasses, albeit the
hydrolysis of IgG4 was incomplete (Fig. 3, panel c).
CP40 is not a general chitinase or broad spectrum
endoglycosidase
In order to investigate if the observed activity of CP40
on IgG could be attributed to a general endochitinase
activity, CP40 was incubated with the well-characterized
fluorogenic chitinase substrate 4 MB-GlcNAc. We have
recently established that the related enzyme EndoS and
its homolog EndoSd are not general endochitinases [33].
Therefore EndoSd was used as a negative control, while
a verified chitinase from Streptomyces griseus was used
as a positive control. This revealed that there is no de-
tectable activity of CP40 on 4 MB-GlcNAc, clearly
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indicating that CP40 is not a general endochitinase
(Fig. 4, panel a).
To elucidate if CP40 has a broader activity on N-
linked glycans on glycoproteins, the enzyme was tested
for activity against the purified glycoproteins IgA, IgE,
IgD, IgM, fetuin, α1-acid glycoprotein (AGP), and
human lactoferrin (hLF). As a positive control PNGase
F, known to hydrolyze all mammalian N-linked glycans,
was used. After incubation, samples were analyzed
SDS-PAGE to assess possible size shifts. This revealed
that no obvious size shifts could be observed when gly-
coproteins were incubated with CP40, in sharp contrast
to PNGase F, where clear size shifts could be observed
(Fig. 4, panel b). These results indicate that CP40 has no
major activity on the glycoproteins tested here.
CP40 is not a protease
During the initial characterization of CP40, a recombinant
protein with a thrombin cleavable tag was used. Based on
gelatin zymography of the thrombin cleaved recombi-
nantly expressed CP40 and culture supernatants from C.
pseudotuberculosis strain WA1030 and the use of specific
protease inhibitors, it was concluded that CP40 is a serine
protease [27]. We attempted to repeat this experiment
using recombinantly expressed CP40 and essentially the
same gelatin zymography method. This revealed that there
was no detectable clearing zone around CP40 in the
zymogram, while there was a distinct clearing zone in the
positive control corresponding to an elastase in Pseudo-
monas aeruginosa culture supernatant (Fig. 5).
CP40 hydrolyzes biantennary, but not bisecting glycans
on IgG
In order to elucidate the glycoform preferences of CP40
in more detail, we turned to HPLC analysis of released
Fig. 1 CP40 is similar to bacterial endoglycosidases. a. The amino acid sequence of CP40 was aligned with a number of endoglycosidases
and serine proteases from different bacterial species. CP40 is enclosed by a rectangle. A phylogenetic tree was reconstructed using the
neighbor-joining method, validated by bootstrapping (10,000 replications) generating a consensus tree. Numbers on branching points
shows the percentage of resampling trees supporting the consensus tree. GenBank accession numbers of the proteins are indicated in front of the
name of each enzyme. The asterisks indicate the serine proteases. b. The putative family 18 glycosyl hydrolase active site of CP40 was aligned with the
verified active sites of EndoE from E. faecalis and EndoS from S. pyogenes
Fig. 2 IgG N-glycan hydrolyzing activity can be detected during
growth of C. pseudotuberculosis. a. C. pseudotuberculosis was grown in
100 ml BHI. After 4 h, 500 μl of human plasma was added to the
culture. 1 ml samples were taken from the bacterial culture after 8,
10,12, 24 h. IgG was purified from the culture and IgG glycan hydrolysis
was analyzed by SDS-PAGE and LCA blot. b. The OD of bacterial culture
was measured at 600 nm at the indicated time point
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glycans. CP40, EndoS, or PNGase, were used to release
glycans from human and ovine IgGs (Since C. pseudotu-
berculosis causes CLA mostly in sheep), and glycans
were subsequently fluorescently labeled and analyzed
using a glycan dedicated hydrophilic interaction liquid
chromatography (HILIC) system. Comparison of the
resulting chromatograms from CP40 and EndoS indicate
that the glycan cleavage site of CP40 is identical to that
of EndoS (Fig. 6). Furthermore, the chromatograms of
CP40 generated glycans indicate that this enzyme can
hydrolyze all biantennary glycoforms from human and
ovine IgGs with the notable exception of structures
containing a bisecting GlcNAc (Fig. 6).
Discussion
CLA in sheep caused by C. pseudotuberculosis is a globally
important disease that has proven to be difficult to control
[34]. Control of the disease is of substantial commercial
interest since CLA causes economical losses due to re-
duced productivity in the dairy, meat and leather indus-
tries [24]. Since the vaccines against the different
virulence factors of the bacteria such as phospholipase D
(PLD) toxin do not induce strong immunity to CLA, re-
searchers are looking for new protective and immuno-
genic antigens [35]. There are also difficulties associated
with using current commercial vaccines due to their lim-
ited efficacy as well as regulations in some countries [35].
Towards that end, CP40 is highly interesting since it has
been established as a major antigen expressed during in-
fection and animals seroconvert to this protein. Most im-
portantly, CP40 immunization generates protective
immunity in both sheep and mice [26, 36, 37]. CP40 has
undoubtedly been established in the literature as one the
most important secreted proteins from C. pseudotubercu-
losis. Even though is it not essential for vaccine strategies
to completely understand the function of the antigen, mo-
lecular characterization can strengthen the basis for tar-
geting the antigen, and most importantly, can increase the
understanding of the basic biology of the infective agent.
We have during a number of years been specializing in
the characterization of bacterial endoglycosidases with
Fig. 3 CP40 hydrolyzes N-linked glycans on human and animal IgG.
a. Recombinant CP40 (0.5 μg) was incubated with to 1 μg of
human. As controls, 0.5 μg of MBP and PNGases F were incubated
with human IgG. b. ovine, equine, bovine and caprine IgG (1 μg)
were incubated with 0.5 μg of CP40 and EndoS. c. All subclasses of
human IgG (1 μg) were incubated with 0.5 μg of recombinant CP40.
All of the reactions were at 37 °C for 2 h and IgG glycan hydrolyzing
was analyzed by SDS-PAGE and LCA blot
Fig. 4 CP40 is not a general chitinase and does not show
glycosidase activity on several glycoproteins. a. CP40, EndoSd, MBP
and a chitinase from S. griseus were incubated with the fluorescent
substrate 4MU-GlcNAc for 1 h and fluorescence was measured at
355/460 nm. The experiments were performed in five replicates.
Data are presented as mean ± S.D. The absorbance was analyzed
statistically by One-way Anova followed up by Tukey’s multiple
comparisons test. ****P < 0.0001. b. Recombinant CP40 (0.5 μg) was
incubated with fetuin, IgE, IgA, IgD, IgM, AGP, hLF for 2 h at 37 °C
and glycan hydrolyzing activity were analyzed by SDS-PAGE
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activity of host glycoproteins. During that CP40 has
again and again showed up as an odd bird when doing
searches with one of our characterized endoglycosidases
(data not shown). Furthermore, recent whole genome
sequencing projects of different corynebacteria have
started to question the annotation of CP40 as a protease
and instead link it to endoglycosidase activity [28, 38].
This in combination with our bioinformatic analysis of
CP40 strongly suggested that this protein is not a prote-
ase, but an endoglycosidase belonging to the GH18
family. Since the protein is fairly small, the likelihood of
an additional protease domain is very low. However,
since annotation of function based on bioinformatics
can be quite ambiguous, clear experimental evidence
was needed in order to annotate a completely new func-
tion to CP40. When attempting to reproduce the
original finding that CP40 has activity against gelatin in
zymography [27], we were not able to see any protease
activity of the protein (Fig. 5). Size shift of IgG on SDS-
PAGE and lack of signal on LCA blot during bacterial
growth, suggests that C. pseudotuberculosis express IgG
glycan hydrolyzing activity (Fig. 2). This could be attrib-
uted to expression of CP40, but we cannot formally
exclude that the bacteria express additional enzymes
with activity on IgG. Our interpretation is that CP40 is
not a protease, and that the previously detected serine
protease activity is most likely due to remaining throm-
bin in the recombinant CP40 preparation, and an unre-
lated serine protease activity in the culture medium of
the C. pseudotuberculosis.
Bacterial endoglycosidases has been extensively used as
tools in glycobiology research, but have been somewhat
overlooked in pathogenesis research [10]. However, since
glycobiology of the immune system, or glycoimmunology,
is getting more attention, bacterial modification of glyco-
proteins beyond mere nutrient acquisition is indeed rele-
vant to study in detail [9]. The activity of GH18 enzymes
ranges from chitinase activity that hydrolyzes basically any
polymer of GlcNAc, to more specific enzymes that
hydrolyses the chitobiose core in certain glycoforms on
any glycoprotein, and enzymes that are both glycoform
and protein specific as exemplified by EndoS, EndoS2,
EndoE, and EndoSd [12, 30, 33, 39]. Based on the simi-
larities to the verified IgG glycan hydrolases EndoE and
EndoS, we first analyzed if CP40 could hydrolyze gly-
cans in IgG from different sources, and in the case of
human IgG, also of different subclasses (Fig. 3). This re-
vealed that bovine and caprine IgG treated with CP40
were intact, while equine IgG was complete hydrolyzed.
All animal IgGs used in this study contain N-glycosyl-
neuraminic acid (NGNA) at the termini of the IgG gly-
can chain [40]. Furthermore, the total content of
carbohydrate in caprine IgG is much lower than human
and ovine IgG. The amount of core fucosylated, termin-
ally galactosylated and bisecting oligosaccharides on
caprine IgG is also very low compared to human and
ovine IgG [40]. Equine IgG has no detectable bisecting
GlcNAc on the N-glycan chain and bovine IgG has a
very low amount of bisecting glycans on IgG [40].
As mentioned above, many GH18 enzymes have acti-
vity on chitin alone, or in the chitobiose core of N-linked
glycans, irrespective of the protein backbone. We there-
fore tested if CP40 had activity on the widely used
endochitinase substrate 4MU-GlcNAc and compared to
verified chitinases. The results clearly showed that CP40
is not a general chitinase (Fig. 4, panel a).
CP40 seemed to have some preference for IgG, and
there were no detectable activity on a number of other
glycoproteins harboring N-linked glycan, including some
of the other immunoglobulin isotypes (IgA, IgD, and
IgA). However, GH18 enzymes can also display prefer-
ences for certain glycoforms, as exemplified by EndoF1–3
and EndoS/EndoS2 [41, 42]. We therefore turned to
Fig. 5 CP40 is not a protease. Recombinant CP40 (1 μg) was loaded
on a zymogram (0.1 % gelatin SDS-PAGE) and stain free gel in parallel.
Supernatant of P. aeruginosa was used as a positive control
Shadnezhad et al. BMC Microbiology  (2016) 16:261 Page 7 of 10
HPLC analysis of released glycans that has the potential
elucidate the glycoform specificity in more detail. HPLC
chromatograms of CP40 released glycans from human
and ovine IgGs showed that this enzyme could only
hydrolyze biantennary structures and not bisecting
GlcNAc (Fig. 6). This glycoform selectivity closely
resembles that of the EndoS homolog EndoSd from S.
dysgalactiae [33]. Ovine IgG contains bisecting GlcNAc
and high mannose structures compared to human IgG;
it also has terminal NGNA instead of N-acetylneurami-
nic acid (NANA) that is found in human IgG [40]. Previ-
ous studies have suggested that carbohydrate binding
domains are important for releasing bisecting structures
by EndoS, since EndoS lacking carbohydrate binding
domain releases bisecting GlcNAc slower than other
glycoforms [43]. Since CP40 is a much smaller enzyme
than EndoS and lacking putative carbohydrate binding
domains, this could potentially explain the lack of activ-
ity against IgG glycans with bisecting GlcNAc.
Conclusions
We believe that we have presented very strong evidence
for that CP40 is a not a serine protease, but rather an
endoglycosidase with activity on immunologically im-
portant host proteins. Furthermore, during the final
stages of preparation of this manuscript, a review about
virulence factors of C. ulcerans identified the CP40
homolog in this species as a GH18 endoglycosidase with
similarity to the α domain of EndoE from E. faecalis [44].
Similar endoglycosidases in other bacterial pathogens have
Fig. 6 CP40 hydrolyzes biantennary, but not bisecting glycans on IgG glycans from human and ovine IgGs. Glycans were released from human
and ovine IgG by PNGase F, EndoS and CP40 respectively, glycans were with 2AB and analyzed by HILIC. The structures annotated according to
the digested glycan using a series of defined exoglycosidase. The released biantennary glycans from IgG and the cleavage site of the glycan
chain are shown. Monosaccharide identities are shown to the right in the middle and conform to the standard colors and shapes as devised by
the Consortium for Functional Glycomic (www.functionalglycomics.org)
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been suggested to be involved in evasion of the adaptive
immune response, but we have not direct evidence for
that CP40 hydrolyzes IgG glycans in vivo and contributes
to immune evasion. However, a solid body of work done
on CP40 by other research groups shows that CP40 is
indeed expressed in vivo, and that immunity towards this
protein provides protection against infection. This makes
our molecular characterization of this protein relevant,
and may aid in the continued development of vaccines
and antimicrobial strategies to combat infections with C.
pseudotuberculosis.
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